AMPHISTA THERAPEUTICS LIMITED

Active Cambridge

Research and experimental development on biotechnology

64 employees website.com
Life sciences and medical technology Research and experimental development on biotechnology
A

AMPHISTA THERAPEUTICS LIMITED

Research and experimental development on biotechnology

Founded 20 Dec 2017 Active Cambridge, England 64 employees website.com
Life sciences and medical technology Research and experimental development on biotechnology
Accounts Submitted 5 Jan 2026 Next due 30 Sept 2026 5 months remaining
Confirmation Submitted 7 Jan 2026 Next due 20 Dec 2026 8 months remaining
Net assets £-32M £9M 2023 year on year
Total assets £55M £17M 2023 year on year
Total Liabilities £87M £8M 2023 year on year
Charges 2
1 outstanding 1 satisfied

Contact & Details

Contact

Registered Address

The Cori Building Granta Park Great Abington Cambridge CB21 6GQ England

Telephone

0800 000 0000

Email

info@example.com

Website

www.example.com

Full company profile for AMPHISTA THERAPEUTICS LIMITED (11119959), an active life sciences and medical technology company based in Cambridge, England. Incorporated 20 Dec 2017. Research and experimental development on biotechnology. View financials, directors, shareholders, and filings.

Business Summary

This company specializes in providing innovative solutions and services across multiple sectors.

Products & Services

consulting software analytics integration

Reports

Credit Report

In-depth credit score, financial analysis, risk assessment and company intelligence.

Financials

Financials

Period 1 Jan → 31 Dec 2023
Type Total Exemption Full
Next accounts 31 December 2024
Due by 30 September 2025 9 months

Net Assets, Total Assets & Total Liabilities (2018–2023)

Cash in Bank

£42.21M

Decreased by £19.33M (-31%)

Net Assets

-£32.44M

Decreased by £9.04M (-39%)

Total Liabilities

£87.20M

Decreased by £8.17M (-9%)

Turnover

£10.70M

Increased by £8.65M (+421%)

Employees

64

Increased by 17 (+36%)

Debt Ratio

159%

Increased by 26 (+20%)

Financial History

Revenue, profit, EBITDA and key financial figures

2023
Dec Year End
2022
Dec Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

Funding Rounds 3

Investors (9)

Investor NameInvestor SinceParticipating Rounds
Investor 2Apr 2020Series A, Series B
Investor 3Apr 2020Series A
Investor 4Apr 2020Series A

Share Capital

Share Capital

Share allotments and capital structure

24 Allotments 24,348,368 Shares £64.65m Total
Date FromShare ClassShares AllottedAmount RaisedPrice/Share
24 Oct 2025692,104£2.63m£3.8
24 Oct 20252,220£0.222£0
24 Oct 20253,333,330£10.00m£3
19 Sept 2025402,262£40.226£40.226
6 Jun 202413,056£1.306£0

Officers

Officers

1 active 2 resigned
Status
Modis, Louise KellyDirectorIrish,americanEngland526 Mar 2026Active

Shareholders

Shareholders (85)

Forbion Capital Fund V Cooperatief U.a
17.8%
4,399,998
Cooperatieve Gilde Healthcare V U.a
17.8%
4,399,998

Persons with Significant Control

Persons with Significant Control (0)

0 Active 5 Ceased
Ceased

Advent Life Sciences Llp

Ceased 27 Feb 2018

Ceased

Advent Life Sciences Llp

Ceased 12 Dec 2022

Ceased
Ceased

Alessio Ciulli

Ceased 28 Jun 2019

Ceased

Group Structure

Group Structure

No group structure identified

Charges

Charges

1 outstanding 1 satisfied

Properties

Properties

1 leasehold 1 total
AddressTenurePrice PaidDate Added
Suite 4, The Cori Building, Granta Park, Great Abington, Cambridge (CB21 6GP) SOUTH CAMBRIDGESHIRE
Leasehold-8 Feb 2022
Suite 4, The Cori Building, Granta Park, Great Abington, Cambridge (CB21 6GP)
Leasehold
Added 8 Feb 2022
District SOUTH CAMBRIDGESHIRE

Documents

Company Filings

DateCategoryDescriptionDocument
9 Apr 2026CapitalAllotment of shares (GBP 2,477.6202) on 2026-03-18
10 Mar 2026OfficersAppointment of Ms Louise Kelly Modis as director on 2026-03-06
10 Mar 2026OfficersTermination of Antony Mattessich as director on 2026-03-06
7 Jan 2026Confirmation StatementConfirmation statement made on 2025-12-06 with updates
5 Jan 2026AccountsAnnual accounts made up to 2024-12-31
9 Apr 2026 Capital

Allotment of shares (GBP 2,477.6202) on 2026-03-18

10 Mar 2026 Officers

Appointment of Ms Louise Kelly Modis as director on 2026-03-06

10 Mar 2026 Officers

Termination of Antony Mattessich as director on 2026-03-06

7 Jan 2026 Confirmation Statement

Confirmation statement made on 2025-12-06 with updates

5 Jan 2026 Accounts

Annual accounts made up to 2024-12-31

Recent Activity

Latest Activity

Allotment of shares (GBP 2,477.6202) on 2026-03-18

1 weeks ago on 9 Apr 2026

Appointment of Ms Louise Kelly Modis as director on 2026-03-06

1 months ago on 10 Mar 2026

Termination of Antony Mattessich as director on 2026-03-06

1 months ago on 10 Mar 2026

Confirmation statement made on 2025-12-06 with updates

3 months ago on 7 Jan 2026

Annual accounts made up to 2024-12-31

3 months ago on 5 Jan 2026